Search PubMed⌕ Search

Biomedical subjects

H Courtois

Publications and source records attributed to H Courtois.

187 records · Page 11Linked to original sources
PubMedDate not supplied

[Acute cotrimoxazole-induced thrombocytopenia, facilitating role of phenobarbital (author's transl)].

A fifty-year-old-woman treated by phenobarbital for seven months developed an acute thrombocytopenia while taking cotrimoxazole for eight days, because of urinary tract infection. The antifolic effect of these two drugs may be increased when they are taken together, and then may be the cause of hematologic disorders. Therefore the authors think these two drugs must not be given together.

Acute Disease↗
PubMedDate not supplied

[Vasoactive peptides of endothelial origin. Therapeutic perspectives].

The role of the endothelium in vascular tone is well established. New physiopathological concepts were brought about by the discovery of endothelium derived vasoactive substances such as the vasodilators prostacyclin and endothelium-derived relaxing factor (EDRF) or the vasocontrictors endothelin and other putative endothelium-derived contracting factors (EDCF). Their discovery led to new therapeutic concepts in vascular, respiratory and infectious diseases. Prostacyclin is a prostaglandin derived from arachidonic acid which has an inhibitor effect on platelet aggregation. It also has a vasodilator effect on vascular smooth muscles cells. Prostacyclin analogues are choice vasculoactive pharmacological agents for patients with thromboangiitis obliterans or severe peripheral vascular disease, whether arteriosclerotic or not. The effect of EDRF is vascular dilatation, predominately in the arteries but also in the veins, including vessels in grafted tissues. EDRF also inhibits platelet aggregation and adhesion. Inversely, the endothelium can also release EDCF which has a vasoconstrictor effect. Endothelin, a recently identified 2429 kD EDCF is active in both arteries and veins and is implicated in physiologic regulation of vasomotricity.

Arteritis↗
PubMedDate not supplied

[Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].

For curative treatment of deep vein thrombosis, all trials have shown that twice a day low molecular weight heparin were at least as efficacious as unfractionated heparin on clot reduction or stabilisation. Through the unit cost of low molecular weight heparin is higher, the real cost of treatment should take into account not only the cost of the drug, but also the cost of materials used and lab tests as well as the time necessary. We have therefore prospectively compared the operating and overall costs of nadroparin and intravenous heparin treatment of deep vein thrombosis in hospitalised patients (21 with unfractionated heparin and 19 with nadroparin). The results show that low molecular weight heparin is no more expensive than treatment with unfractionated heparin (336 +/- 74.9 F for unfractionated heparin and 344.9 +/- 44.05 F for nadroparin). In addition, using nadroparin rather than heparin saves approximately one hour per patient per week nursing time (42 +/- 7 minutes vs 104.0 +/- 10.7 minutes, p < 0.05). The methodology of this study should be repeated with other low molecular weight heparin and low molecular weight heparin compare not only to standard i.v. heparin, but also to standard SC heparin.

Adult↗
PubMedDate not supplied

[Dyschromatopsia: manifestation or epiphenomenon in the course of diabetic neuropathy].

We performed a study in 92 diabetic patients (76 Type 1 and 16 Type 2) without retinopathy to determine the relation between diabetic dyschromatopsia and neuropathy, which has been evoked in previous studies. Color vision was explored with Lanthony's desaturated D 15 panel. Peripheral nervous function was explored with an electrophysiological score which has been beforehand validated. Moreover evoked visual potentials were performed in 38 diabetic subjects in order to determine whether dyschromatopsia was related to an impairment of central optic pathways. Fifty-one among the 92 diabetic subjects had a blue-yellow dyschromatopsia. Among the recorded parameters, only peripheral nervous impairment was significantly more frequent in the group with dyschromatopsia than in the group without. Ten among 38 diabetics had impairment of the evoked visual potentials. Frequency of alteration of evoked visual potentials was not different between the group with and the group without dyschromatopsia. Our results confirm the relationship between dyschromatopsia and the alteration of the nervous function in diabetic subjects. In return, lack of significant modification of evoked visual potentials among diabetic patients with dyschromatopsia and the blue-yellow axis of dyschromatopsia are in opposition with a direct neurological origin of dyschromatopsia. We therefore evoke a common process in the beginning of the diabetic dyschromatopsia and of peripheral neuropathy.

Adolescent↗